Physician profile

Brian Bean

Internal Medicine · Little Rock, AR

NPI 1003870049

$229.05

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$54.95

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $66.41 2019-2024 Jardiance
Astrazeneca Pharmaceuticals Lp $44.22 2020-2022
Janssen Pharmaceuticals, INC $34.25 2019-2021
Nabriva Therapeutics, Plc $27.66 2020
Novartis Pharmaceuticals Corporation $16.58 2019
Abbvie INC. $15.13 2021
Enterra Medical, INC. $12.87 2023
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $11.93 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Brian Bean

$229.05

in general payments reported 2019-2025

Years
2019-2024
Top company
Boehringer Ingelheim Pharmaceuticals, INC.

https://glasscript.com/doctor/477664/brian-bean

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.